Diabetes drugs sold by Merck & Co. (MRK -0.7%) and Bristol-Myers Squibb Co. (BMY +0.1%) may...

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Diabetes drugs sold by Merck & Co. (MRK -0.7%) and Bristol-Myers Squibb Co. (BMY +0.1%) may double a user’s risk of developing an inflammation of the pancreas linked to cancer and kidney failure, according to a recent study in the journal JAMA Internal Medicine. Analysis of insurance records indicate that patients hospitalized with pancreatitis were twice as likely to be taking Januvia, MRK’s top-selling drug, or BMY’s Byetta, than a control group of diabetics who didn’t have pancreatitis. Both drugs increase GLP-1, a hormone that stimulates insulin production from the pancreas.